Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q3 2018 10-Q quarterly report on Nov 5, 2018 for the quarter ended Sep 30, 2018.
Neurocrine Biosciences Inc Q3 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $151.8M, up $91.0M YoY from $60.8M, driven by INGREZZA sales and collaboration revenue
- INGREZZA sales $111.3M, up $65.5M YoY; collaboration revenue $40.5M, including $40.0M ORILISSA milestone
- Net income $50.8M vs $11.1M loss YoY; operating margin figures not disclosed
- Operating cash flow $50.9M vs $134.9M used YoY; cash, restricted cash and investments $826.1M
- Outlook: resources sufficient for at least 12 months; higher post-approval INGREZZA API costs expected in fourth quarter
Risk Factors
- Newly added risks triggered by INGREZZA commercialization: limited marketing, sales-force, distribution and reimbursement experience
- Most materially updated risk: 2024 Notes became conditionally convertible through December 31, 2018, potentially requiring cash settlement and reducing liquidity
- Regulatory risk: healthcare-law violations could trigger civil or criminal penalties, fines, damages and Medicare or Medicaid exclusion
- Operational risk: single-source suppliers for INGREZZA and its active pharmaceutical ingredients create shortage exposure
- Financial risk: $517.5 million of 2.25% convertible senior notes due 2024 increase refinancing and cash-flow pressure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.